Larimar Reports Positive Long-Term Data on Nomlabofusp in Friedreich’s Ataxia
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) reported new long-term open-label (OL) data for nomlabofusp in Friedreich’s ataxia (FA), showing sustained increases in frataxin (FXN) protein and consistent …
Larimar Reports Positive Long-Term Data on Nomlabofusp in Friedreich’s Ataxia Read More